Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation

Is the use of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the evaluation of biochemical recurrent (BCR) prostate cancer cost-effective in the US?This economic evaluation of modeled patients with prostate cancer found that PSMA-PET had an incremental cost-effectiveness ratio below the willingness-to-pay threshold in patients with BCR and lower prostate-specific antigen levels. However, the decision-analytic model indicated high decision uncertainty and identified that additional data on diagnostic characteristics may be associated with reduction of this uncertainty.This study found that PSMA-PET has the potential to be cost-effective for selected patients with recurrent prostate cancer, but additional evidence is needed to reduce uncertainty about its value across clinical scenarios.

Corresponding Author: Natalia Kunst, PhD, Centre for Health Economics, University of York, Heslington, York YO10 5DD, United Kingdom (natalia.kunst@york.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.